Security
KYTX · Kyverna Therapeutics, Inc.
KYTXNASDAQCommon stockCurrentCIK 1994702Updated Sep 29, 2026
Name history
Kyverna Therapeutics, Inc. · through Sep 24, 2026
KYTX price & chart
Loading TradingView…
NASDAQ:KYTX on TradingView ↗About the company
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).
In the news
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition ↗
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results News provided by Kyverna Therapeutics May 13, 2025, 16:02 ET Share this article Share to X Share this article Share to X Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome ↗
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results News provided by Kyverna Therapeutics Mar 27, 2025, 16:02 ET Share this article Share to X Share this article Share to X Accelerating clinical path to commercialization in stiff person syndr ↗
Seeking Alpha
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow ↗
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript ↗
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
3 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 293,826,000Source | 304,645,000Source | 75,195,000Source |
| Property, Plant and Equipment, NetUSD | 1,546,000Source | 3,347,000Source | 2,326,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 124,093,000Source | 96,621,000Source | 34,647,000Source |
| Assets, CurrentUSD | 282,953,000Source | 290,601,000Source | 60,664,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,700,000Source | 4,622,000Source | 3,121,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,568,000Source | 6,468,000Source | 6,494,000Source |
| Other Assets, NoncurrentUSD | 4,903,000Source | 2,836,000Source | 3,356,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 61,550,000Source | 38,058,000Source | 26,018,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -424,827,000Source | -263,520,000Source | -136,043,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 97,000Source | 105,000Source | 4,000Source |
| Stockholders' Equity Attributable to ParentUSD | 232,276,000Source | 266,587,000Source | -131,397,000Source |
| Additional Paid in Capital, Common StockUSD | 657,005,000Source | 530,002,000Source | 4,642,000Source |
| Liabilities and EquityUSD | 293,826,000Source | 304,645,000Source | 75,195,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 36,487,000Source | 33,756,000Source | 19,859,000Source |
| Operating Lease, Liability, CurrentUSD | 3,662,000Source | 3,161,000Source | 1,964,000Source |
| Accounts Payable, CurrentUSD | 5,306,000Source | 4,624,000Source | 4,358,000Source |
| Operating Lease, Liability, NoncurrentUSD | 320,000Source | 4,160,000Source | 5,238,000Source |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 279,300,000Source | 286,000,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,799,000Source | 2,133,000Source | 1,707,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,080,000Source | 8,357,000Source | 2,220,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 543,000Source | 736,000Source | 4,083,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -153,712,000Source | -114,250,000Source | -52,410,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 40,015,000Source | -160,902,000Source | -8,785,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,000Source | 2,205,000Source | 621,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 141,168,000Source | 337,113,000Source | 58,118,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 27,471,000Source | 61,961,000Source | -3,077,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 415,000Source | 142,000Source | 187,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 10,080,000Source | 8,357,000Source | 2,220,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 279,300,000Source | 286,000,000Source | — |
| DepreciationUSD | 1,100,000Source | 1,200,000Source | 900,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -60,000Source | — | — |
| General and Administrative ExpenseUSD | 36,107,000Source | 30,131,000Source | 12,483,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 489,000Source | 142,000Source | 187,000Source |
| Investment Income, InterestUSD | 9,094,000Source | 15,359,000Source | 2,282,000Source |
| Net Income (Loss) Attributable to ParentUSD | -161,307,000Source | -127,477,000Source | -60,366,000Source |
| Nonoperating Income (Expense)USD | 8,520,000Source | 15,127,000Source | 2,040,000Source |
| Operating ExpensesUSD | 169,827,000Source | 142,604,000Source | 62,406,000Source |
| Other Nonoperating Income (Expense)USD | -85,000Source | -90,000Source | -55,000Source |
| Proceeds from Issuance of Common StockUSD | 16,940,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 1,987,000Source | 259,000Source | 645,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -169,827,000Source | -142,604,000Source | -62,406,000Source |
| Other Nonoperating Income (Expense)USD | -85,000Source | -90,000Source | -55,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -161,307,000Source | -127,477,000Source | -60,366,000Source |
| Earnings Per Share, BasicUSD per share | -3.64Source | -3.33Source | -89.61Source |
| Earnings Per Share, DilutedUSD per share | -3.64Source | -3.33Source | -89.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,259,999Source | 38,334,571Source | 673,622Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 44,259,999Source | 38,334,571Source | 673,622Source |
| Interest Expense (non-operating)USD | 489,000Source | 142,000Source | 187,000Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 36,107,000Source | 30,131,000Source | 12,483,000Source |
| Investment Income, InterestUSD | 9,094,000Source | 15,359,000Source | 2,282,000Source |
| Nonoperating Income (Expense)USD | 8,520,000Source | 15,127,000Source | 2,040,000Source |
| Operating ExpensesUSD | 169,827,000Source | 142,604,000Source | 62,406,000Source |
| Research and Development ExpenseUSD | 133,720,000Source | 112,473,000Source | 49,923,000Source |
Filing attachments
kytx-ex99_1.htm · 8-K · 2026-09-24
Exhibit 99.1 Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical benefit and reversal of disability through one year support the potentia…
Read attachment ↗kytx-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 kytx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2…
Read attachment ↗kytx-ex99_1.htm · 8-K · 2026-07-27
EX-99.1 2 kytx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune di…
Read attachment ↗kytx-ex99_1.htm · 8-K · 2026-05-18
EX-99.1 4 kytx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyverna Therapeutics Names Greg Martini as Chief Financial Officer Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth EMERYVILLE, Calif., May 18, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Greg Martini as Chief Financial Officer (CFO), effective …
Read attachment ↗kytx-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 kytx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS demonstrated robust, durable effect in indication with no approved therapies; launch preparations continue with appoin…
Read attachment ↗kytx-ex99_1.htm · 8-K · 2026-05-04
EX-99.1 2 kytx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas EMERYVILLE, Calif., May 4, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell…
Read attachment ↗